Objective:To explore the clinical efficacy and quality of life of patients with chronic gastritis(CG)treated with rabeprazole+magnesium aluminocarbate chewable tablets.Methods:A total of 60 patients with CG who were admitted in our hospital from January 2021 to December 2022 were selected,and by random number table method,they were divided into the study group(n=30)and the control group(n=30).Magnesium aluminate chewable tablets was treated with the control group,and rabeprazole+magnesium aluminate chewable tablets was treated with the study group.The clinical efficacy,clinical symptom relief time,clinical symptom score and quality of life of the two groups were compared.Results:In comparision of the control group(73.33％),the total effective rate of the study group(96.67％)was higher(P＜0.05).In comparision of the control group,the relieving time of abdominal distension,abdominal pain,acid regurgitation and belching symptoms in the study group was shorter(P＜0.05).After 2 weeks of treatment,the clinical symptom scores(nausea and vomiting,epigastric pain,loose stool)in both groups were decreased(P＜0.05),and in comparision of the control group,the scores in the study group were lower(P＜0.05).After 2 weeks of treatment,the scores of WHOQOL-BREF in both groups were increased(P＜0.05),and in comparision of the control group,the study group was higher(P＜0.05).Conclusion:Rabeprazole+magnesium aluminocarbate chewable tablets can improve the clinical efficacy,shorten the time to relieve clinical symptoms,alleviate clinical symptoms and improve the quality of life in the treatment of CG.
RabeprazoleMagnesium aluminum carbonate chewable tabletsChronic gastritisClinical efficacyQuality of life
万方数据
维普
